MBIA Inc ( (MBI) ) has released its Q4 earnings. Here is a breakdown of the information MBIA Inc presented to its investors.
MBIA Inc, a prominent player in the diagnostic medicine sector, has reported robust financial results for the year 2024, showcasing its strategic growth and operational efficiency. The company, known for its comprehensive healthcare services, has successfully integrated Grupo Fleury and Pardini, expanding its geographic reach and service portfolio.
In 2024, MBIA Inc achieved a gross revenue of R$ 8.3 billion, marking a 19.5% increase over the previous year. The company’s EBITDA reached R$ 1.982 billion, reflecting a 19.6% growth, while net income rose by 32% to R$ 616.2 million. This growth was driven by strong performances across various brands and regions, with notable expansions in mobile services and B2B segments.
Key highlights include a significant increase in gross profit, reaching R$ 453.6 million with a margin of 24.7%. The company also reported a reduction in leverage to 1.0x and a decrease in the cost of debt, alongside a Moody’s rating upgrade to AAA.br stable. Strategic acquisitions, such as Grupo São Lucas and Confiance Diagnostic Medicine, further bolstered MBIA Inc’s market position.
Looking ahead, MBIA Inc remains committed to its strategic objectives, focusing on innovation and operational efficiency to sustain its leadership in the healthcare sector. The company aims to continue its disciplined capital allocation and explore new growth opportunities in 2025.